Key facts
- KineoLabs’s last known valuation is $11.5M (Jan 2026).
- It has raised $4.1M across 4 recorded rounds; the latest was Seed Round ($1.0M) in Dec 2025.
- KineoLabs has filed 4 Form Ds with the SEC since 2022, most recently May 2025 ($700K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for KineoLabs
Funding rounds
4 roundsAbout KineoLabs
Developer of next-generation optical coherence tomography instruments designed for early disease detection and disease monitoring. The company helps to streamline assessments through a portable device, high-resolution imaging, and reduction of monitoring equipment and technicians needed, enabling healthcare and industrial professionals to improve accuracy and reduce costs of automated disease examinations.
- Sector
- Healthcare
- HQ
- Billerica, MA, United States
- Founded
- 2021
- Employees
- 8
- Website
- kineolabs.com/
- Ownership
- Privately Held (backing)
KineoLabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KineoLabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KineoLabs in its N-PORT filings yet. We sweep new filings monthly.